Form 4: BioCryst Pharmaceuticals Executive Charles K. Gayer Acquires 30,000 Shares

Chief Commercial Officer of BioCryst Pharmaceuticals, Charles K. Gayer, purchased 30,000 shares of common stock at $5.47 per share on May 13, 2024.

Summary

• On May 13, 2024, Charles K. Gayer, the Chief Commercial Officer of BioCryst Pharmaceuticals, acquired 30,000 shares of the company's common stock.
• The purchase price was $5.47 per share.
• Following the transaction, Gayer directly owns 307,533 shares of BioCryst Pharmaceuticals.
• The transaction was reported on a Form 4 filing with the SEC on May 15, 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as an insider purchase generally signals confidence in the company's prospects. However, it's a single transaction and needs to be considered in the broader context of the company's performance.

Positives

• An executive's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Insider transactions are closely monitored by investors as they can provide insights into a company's performance and future expectations. Purchases are generally viewed more positively than sales.

Stakeholder Impact

• The stock purchase could positively influence shareholder sentiment.

Key Dates